Acionna Therapeutics

Alzheimer’s disease remains one of the greatest challenges in modern healthcare, with few effective therapies available despite growing global need.

Acionna is developing a pipeline of novel therapeutics that target the neuroimmune cascade to improve synaptic function. This approach holds promise not only for Alzheimer’s disease but also for other central nervous system disorders.

Built on pioneering research from the University of Oxford and Cardiff University – funded by Alzheimer’s Research UK and the UK Dementia Research Institute – Acionna is advancing a new way to treat neurodegenerative disease.